Fibroblast growth factors (a family of 22 distinct polypeptides) and their transmembrane tyrosine kinase receptors (FGFR1-FGFR4) play a critical role in several cancers.1 Overexpression, gain-of-function mutations and gene fusions are the main aberrant alterations leading to oncogenic function of FGFR.2 Lucitanib and dovitinib were the first nonselective FGFR tyrosine kinase inhibitors (TKIs) investigated in advanced cancers.
Bétrian S, Gomez-Roca C, Vigarios E, Delord JP, Sibaud V. Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors. JAMA Dermatol. 2017;153(7):723–725. doi:10.1001/jamadermatol.2017.0500
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: